Infants Receiving a Single Dose of Nirsevimab to Prevent RSV Do Not Have Evidence of Enhanced Disease in Their Second RSV Season
JOURNAL OF THE PEDIATRIC INFECTIOUS DISEASES SOCIETY(2024)
摘要
To characterize nirsevimab in the prevention of RSV, children from the Phase 3 MELODY trial were followed through their second RSV season. No increase in medically attended RSV lower respiratory tract infections or evidence of antibody-dependent enhancement of infection or disease severity was found for nirsevimab vs placebo recipients.Clinical Trial Registration : Clinicaltrials.gov, NCT03979313, https://clinicaltrials.gov/ct2/show/NCT03979313. No increase in the incidence of medically attended RSV lower respiratory tract infection or evidence of antibody-dependent enhancement of disease was found among nirsevimab recipients during their second RSV season in the Phase 3 MELODY trial compared with placebo recipients.
更多查看译文
关键词
immunization,monoclonal antibody,nirsevimab,respiratory syncytial virus
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要